It is important to establish reference drugs as the positive control with efficacy for tumor growth inhibition. Two drugs (Vandetanib and Paclitaxel) for FaDu tumor (head and neck cancer, squamous cell) treatment are effective in our model.

Vandetanib is a small-molecule tyrosine kinase inhibitor (TKI) with dual specificity for EGFR and VEGFR; and FaDu cells overexpress EGFR therefore Vandetanib is a good agent for FaDu therapy. Paclitaxel is a mitotic inhibitor used in cancer chemotherapy which is also valid for FaDu treatment in our model.